Low-dose thalidomide in myeloma: Efficacy and biologic significance

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 17, 2002, Pages 34-38

  Durie, Brian G M ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Salick Health Care Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DEXAMETHASONE; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MACROPHAGE; MONOTHERAPY; MYELOMA; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SKIN DISEASE; SKIN MANIFESTATION; SKIN TINGLING; THROMBOPHLEBITIS;

EID: 0037245766     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70059-6     Document Type: Article

References (31)

1. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
2. Durie BGM, Stepan DE: Low dose thalidomide alone and in combination: Long term follow-up. Presented at the American Society of Hematology 43rd Annual Meeting, December 2001, Orlando, FL (abstr 688)
3. Moreira AL, Sampaio EP, Zmuidzinas A, et al: Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993
4. Moller DR, Wysocka M, Greenlee BM, et al: Inhibition of IL-12 production by thalidomide. J Immunol 159:5157-5161, 199
5. Kubin M, Chow JM, Trinchieri G: Differential regulation of interleukin-12 (IL-12), tumor necrosis factor a and IL-1β production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 83:1847-1855, 1994
6. D'Andrea A, Ma X, Aste-Amezega M, et al: Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: Priming for IL-12 and tumor necrosis factor a production. J Exp Med 181:537-546, 1995
7. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl Acad Sci U S A 90:5974-5978, 1993
8. Clerici M, Lucey DR, Berzofsky JA, et al: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721-1724, 1993
9. 1-acid glycoprotein. Nature 281:677-678, 1979
10. Klein B, Bataille R: Cytokines network in human multiple myeloma. Hematol Oncol Clin North Am 6:243-284, 1992
11. Carter A, Merchav S, Draxler I, et al: The role of interleukin-1 and tumour necrosis factor-a in human multiple myeloma. Br J Haematol 74:424-431, 1990
12. Bataille R, Manolagas SC, Berenson JR: Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11:349-361, 1997
13. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76:949-962, 1994
14. Sen R, Baltimore D: Inducibility of κ immunoglobulin enhancer-binding protein NFκB by a posttranslation mechanism. Cell 47:921-928, 1986
15. Lichtenstein M, Keini G, Cedar H, et al: B cell-specific demethylation: A novel role for the intronic κ chain enhancer sequence. Cell 76:913-923, 1994
16. Kirillov A, Kistler B, Mostoslavsky R, et al: A role for nuclear NFκB in B-cell specific demethylation of the Igk locus. Nat Genet 13:435-441, 1996
17. Darnay BG, Ni J, Moore PA, et al: Activation of NFκB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NFκB-inducing kinase. J Biol Chem 274:7724-7731, 1999
18. Wong BR, Besser D, Kim N, et al: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4:1041-1049, 1999
19. Baeuerle PA, Baltimore D: NFκB: Ten years after. Cell 87:13-20, 1996
20. Ghosh S, May NJ, Kopp EB: NFκB and REL proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998
21. Abu-Amer Y, Tondravi MM: NFκB and bone: the breaking point. Nat Med 3:1189-1196, 1997
22. Stinchcombe TE, Mitchell BS, Depcik-Smith N: PS-341 is active in multiple myeloma: A preliminary report of a phase I trial in patients with hematologic malignancies. Blood 96:516a, 2000 (abstr 2219)
23. Durie BGM, Christiansen JA: Improved human myeloma colony growth. Blood 62:189a, 1983 (abstr)
24. Zangari M, Anaissie M, Barlogie B, et al: Increased risk of thrombophlebitis in myeloma patients receiving thalidomide combination therapy. Blood 98:1614-1615, 2001
25. Bucala R: The effects of the signaling molecule MIF are quite well understood, but how it works remains a mystery: Some of the pathways behind its activity have now been revealed - with surprising results. Nature 408:146-147, 2000
26. Hudson JD, Shaibi MA, Maestro R, et al: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375-1382, 1999
27. Metz CN, Bucala R: Role of macrophage migration inhibitory factor in the regulation of the immune response: advances in immunology. Adv Immunol 66:197-223, 1997
28. Durie BGM, Colins PA, Martin WJ: Positive stealth virus cultures in myeloma patients: A possible explanation for neuropsychiatric comorbidity. Blood 96:2000 (suppl 1) (abstr 1553)
29. Casarosa P, Bakker PA, Verzijl D, et al: Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 276:1133-1137, 2001
30. Sjak-Shie NN, Vescio RA, Manyak SJ, et al: Clarithromycin adds to the efficacy of steroid therapy with/without thalidomide in multiple myeloma: Clinical and laboratory evidence. Proceedings of the VIIIth International Myeloma Workshop, May 2001, Banff, Canada. (abstr P158)
31. Coleman M: Efficacy of Biaxin, low dose thalidomide and dexamethasone (BLT-D) combination in multiple myeloma and waldenstrom's macroglobulinemia. Proceedings of the VIIIth International Myeloma Workshop, May 2001, Banff, Canada.